VIA
EVGN icon

Vident Investment Advisory’s Evogene EVGN Stock Holding History

Vident Investment Advisory’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,771
Closed -$68K – 1173
2022
Q2 		$68K Buy
8,771
+384
+5% +$3.75K ﹤0.01% 1222
2022
Q1 		$109K Buy
8,387
+3,408
+68% +$46K ﹤0.01% 1228
2021
Q4 		$82K Buy
4,979
+263
+6% +$5.97K ﹤0.01% 1187
2021
Q3 		$125K Buy
+4,716
New +$138K ﹤0.01% 1118

Other funds holding EVGN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Vident Investment Advisory's EVGN Position: Q3 2022 in Review

Vident Investment Advisory sold out of Evogene (EVGN) in Q3 2022, closing a stake of 8,771 shares — an estimated $68K sold.

Vident Investment Advisory first reported a position in EVGN in Q3 2021 and held it in 4 quarters. The position peaked at $125K in Q3 2021. 26 funds tracked by Wall St. Rank hold EVGN as of Q3 2022.

  • Vident Investment Advisory reported no remaining Evogene position as of Q3 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 8,771 Evogene shares in Q3 2022, an estimated $68K.
  • Vident Investment Advisory first reported a position in Evogene in Q3 2021 and held it in 4 quarters.
  • Vident Investment Advisory's Evogene position peaked at $125K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Evogene as of Q3 2022.

Based on Vident Investment Advisory's 13F filing for Q3 2022, filed 14 Nov 2022.